Pharmacokinetics and Bioavailability of the Novel Rivastigmine Transdermal Patch Versus Rivastigmine Oral Solution in Healthy Elderly Subjects

The Journal of Clinical PharmacologyVolume 48, Issue 2 p. 246-252 Pharmacokinetics and Bioavailability of the Novel Rivastigmine Transdermal Patch Versus Rivastigmine Oral Solution in Healthy Elderly Subjects Dr Gilbert Lefèvre PhD, Corresponding Author Dr Gilbert Lefèvre PhD Novartis Pharma AG, Basel, Switzerland Address for correspondence: Dr G Lefèvre, Novartis Pharma AG, Exploratory Development, WSJ-210.4.25, CH-4002 Basel, Switzerland; e-mail: gilbert.lefevre@novartis.com.Search for more papers by this authorMrs Françoise Pommier, Mrs Françoise Pommier Novartis Pharma SAS, Rueil-Malmaison, FranceSearch for more papers by this authorDr Greg Sędek MD, PhD, Dr Greg Sędek MD, PhD Novartis Pharmaceuticals Corporation, East Hanover, New JerseySearch for more papers by this authorDr Mark Allison MD, Dr Mark Allison MD MDS Pharma Services, Phoenix, ArizonaSearch for more papers by this authorDr Hsun-Lun Aaron Huang PharmD, Dr Hsun-Lun Aaron Huang PharmD Novartis Pharmaceuticals Corporation, East Hanover, New JerseySearch for more papers by this authorMrs Beate Kiese MSc, Mrs Beate Kiese MSc Novartis Pharma AG, Basel, SwitzerlandSearch for more papers by this authorDr Yu-Yun Ho PhD, Dr Yu-Yun Ho PhD Novartis Pharmaceuticals Corporation, East Hanover, New JerseySearch for more papers by this authorDr Silke Appel-Dingemanse PhD, Dr Silke Appel-Dingemanse PhD Novartis Pharma AG, Basel, SwitzerlandSearch for more papers by this author Dr Gilbert Lefèvre PhD, Corresponding Author Dr Gilbert Lefèvre PhD Novartis Pharma AG, Basel, Switzerland Address for correspondence: Dr G Lefèvre, Novartis Pharma AG, Exploratory Development, WSJ-210.4.25, CH-4002 Basel, Switzerland; e-mail: gilbert.lefevre@novartis.com.Search for more papers by this authorMrs Françoise Pommier, Mrs Françoise Pommier Novartis Pharma SAS, Rueil-Malmaison, FranceSearch for more papers by this authorDr Greg Sędek MD, PhD, Dr Greg Sędek MD, PhD Novartis Pharmaceuticals Corporation, East Hanover, New JerseySearch for more papers by this authorDr Mark Allison MD, Dr Mark Allison MD MDS Pharma Services, Phoenix, ArizonaSearch for more papers by this authorDr Hsun-Lun Aaron Huang PharmD, Dr Hsun-Lun Aaron Huang PharmD Novartis Pharmaceuticals Corporation, East Hanover, New JerseySearch for more papers by this authorMrs Beate Kiese MSc, Mrs Beate Kiese MSc Novartis Pharma AG, Basel, SwitzerlandSearch for more papers by this authorDr Yu-Yun Ho PhD, Dr Yu-Yun Ho PhD Novartis Pharmaceuticals Corporation, East Hanover, New JerseySearch for more papers by this authorDr Silke Appel-Dingemanse PhD, Dr Silke Appel-Dingemanse PhD Novartis Pharma AG, Basel, SwitzerlandSearch for more papers by this author First published: 07 March 2013 https://doi.org/10.1177/0091270007312154Citations: 26Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume48, Issue2February 2008Pages 246-252 RelatedInformation